Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines for neurological diseases. Its products include LP352, a Phase I clinical trial product for the developmental and epileptic encephalopathies (DEEs) and refractory epilepsies; LP143, a product for amyotrophic lateral sclerosis and other neuroinflammatory disorders; and LP659, a product for multiple neuroinflammatory disorders. Longboard Pharmaceuticals, Inc. was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. The company was founded in 2020 and is based in San Diego, California.
IPO Year: 2021
Exchange: NASDAQ
Website: longboardpharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/10/2024 | $60.00 | Buy | Truist |
| 7/1/2024 | $60.00 → $90.00 | Overweight | Cantor Fitzgerald |
| 5/1/2024 | $36.00 | Outperform | Robert W. Baird |
| 2/16/2024 | $40.00 | Buy | Citigroup |
| 10/24/2023 | $16.00 → $35.00 | Overweight | Cantor Fitzgerald |
| 4/27/2023 | $13.00 | Buy | B. Riley Securities |
| 2/14/2022 | $14.00 | Outperform | Wedbush |
DEEp OCEAN is the first pivotal clinical trial designed to study DEEs broadly Initial sites activated with additional sites expected to be activated in the coming weeks Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has initiated its global Phase 3 DEEp OCEAN Study evaluating its investigational drug bexicaserin for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) in participants two years of age and older. "The initiation of our second global Phase 3 clinical trial, DEEp OCEAN in DEEs, is a
Positive opinion of Paediatric Investigation Plan for bexicaserin issued by European Medicines Agency (EMA) Paediatric Committee (PDCO) for children down to the age of 2 years Recently initiated Phase 3 global clinical trial (the DEEp SEA Study) to evaluate bexicaserin in Dravet syndrome for participants ages 2-65 years Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported third quarter 2024 financial results. RECENT UPDATES: In October, announced an agreement for H. Lundbeck A/S (Lundbeck) to acquire Longboard in a stra
The proposed acquisition represents a significant step forward in Lundbeck's Focused Innovator strategy, adding a highly innovative and complementary product in late-stage development for Developmental and Epileptic Encephalopathies (DEEs) - an area of high unmet medical need The acquisition will enhance and complement Lundbeck's capabilities and presence within neuro-rare conditions The lead asset, bexicaserin, holds blockbuster potential and is in development for the treatment of DEEs in a program enrolling patients diagnosed with Dravet syndrome, Lennox-Gastaut syndrome, and other DEE syndromes Bexicaserin has shown encouraging anti-seizure effects to date in preclinical and clini
Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to three new employees. The Compensation Committee of the Board of Directors of Longboard approved the grants of non-qualified stock options to purchase an aggregate of 56,000 shares of its common stock (the "Common Stock") and 35,000 restricted stock units ("RSUs") as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options and RSUs were granted on September 30, 2024 (the "Grant Date"
First sites activated with a number of additional rapid-start sites being activated in the coming weeks Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has initiated its global Phase 3 DEEp SEA Study evaluating its investigational drug bexicaserin for the treatment of seizures associated with Dravet syndrome in participants two years of age and older. "We are thrilled to announce the initiation of our global Phase 3 DEEp Program with our first sites activated and multiple additional sites primed for activation within the next couple of weeks
U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation and Rare Pediatric Disease designation for bexicaserin for the treatment of Dravet syndrome Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that the FDA has granted Rare Pediatric Disease designation and Orphan Drug designation for its investigational drug bexicaserin for the treatment of Dravet syndrome. "We are thrilled to receive both Rare Pediatric Disease and Orphan Drug designations for bexicaserin in Dravet syndrome. As the first company to receive Breakthrough Therapy
Bexicaserin achieved an overall median seizure reduction of 57.7% in countable motor seizures over an approximate 9-month treatment period Favorable safety and tolerability results continue to be observed Data to be presented at the 15th European Epilepsy Congress in Rome, Italy Full 12-month OLE dataset expected early next year Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced positive interim results from its ongoing 52-week open-label extension of the PACIFIC Study evaluating bexicaserin (LP352) in participants ages 12-65 years old with Develop
Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to eleven new employees. The Compensation Committee of the Board of Directors of Longboard approved the grants of non-qualified stock options to purchase an aggregate of 203,500 shares of its common stock (the "Common Stock") as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options were granted on August 31, 2024 (the "Grant Date") and have an exercise price of $36.08 per share, wh
Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its leadership team will participate in four upcoming investor conferences. CONFERENCE DETAILS: Event: Wells Fargo Healthcare Conference Details: Hosting investor meetings on Thursday, September 5, 2024, in Boston, MA Event: H.C. Wainwright Global Investment Conference Details: Presenting in a fireside chat format on Tuesday, September 10, 2024, at 12:00 PM ET and hosting investor meetings in New York, NY Event: Baird's Global Healthcare Conference Details: Presenting in a fireside c
Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will present data at the International League Against Epilepsy (ILAE) 15th Annual European Epilepsy Congress which is taking place in Rome, Italy from September 7-11, 2024. "ILAE is one of the premier medical organizations in the epilepsy space and we look forward to participating in this important meeting, which brings together key opinion leaders from across Europe and the rest of world. As we prepare for the initiation of our global Phase 3 program this year, this conference will help us contin
SC TO-T/A - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)
SC 14D9/A - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)
SC TO-T/A - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)
10-Q - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)
8-K - Longboard Pharmaceuticals, Inc. (0001832168) (Filer)
SC TO-T/A - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)
SC 14D9/A - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)
SC 14D9 - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)
SC TO-T - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)
SC TO-C - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)
4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)
SC 13G/A - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)
SC 13G/A - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)
SC 13G/A - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)
SC 13G/A - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)
SC 13G/A - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)
SC 13G/A - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)
SC 13G/A - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)
SC 13G - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)
SC 13G/A - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)
SC 13G/A - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)
4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)
4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)
4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)
4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)
4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)
4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)
4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)
4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)
4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)
4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)
Truist initiated coverage of Longboard Pharmaceuticals with a rating of Buy and set a new price target of $60.00
Cantor Fitzgerald reiterated coverage of Longboard Pharmaceuticals with a rating of Overweight and set a new price target of $90.00 from $60.00 previously
Robert W. Baird initiated coverage of Longboard Pharmaceuticals with a rating of Outperform and set a new price target of $36.00
Citigroup initiated coverage of Longboard Pharmaceuticals with a rating of Buy and set a new price target of $40.00
Cantor Fitzgerald resumed coverage of Longboard Pharmaceuticals with a rating of Overweight and set a new price target of $35.00 from $16.00 previously
B. Riley Securities initiated coverage of Longboard Pharmaceuticals with a rating of Buy and set a new price target of $13.00
Wedbush initiated coverage of Longboard Pharmaceuticals with a rating of Outperform and set a new price target of $14.00
Evercore ISI Group initiated coverage of Longboard Pharmaceuticals with a rating of Outperform and set a new price target of $35.00
Guggenheim initiated coverage of Longboard Pharmaceuticals with a rating of Buy and set a new price target of $27.00
Cantor Fitzgerald initiated coverage of Longboard Pharmaceuticals with a rating of Overweight and set a new price target of $32.00
Baird analyst Joel Beatty maintains Longboard Pharmaceuticals (NASDAQ:LBPH) with a Outperform and raises the price target from $36 to $60.
As of July 3, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro. Here's the latest list of major overbought players in this sector. Harrow Inc (NASDAQ:HROW) On June 21, Craig-Hallum analyst Chase Knickerbocker maintained Har
Citigroup analyst David Hoang maintains Longboard Pharmaceuticals (NASDAQ:LBPH) with a Buy and raises the price target from $40 to $45.
Evercore ISI Group analyst Josh Schimmer maintains Longboard Pharmaceuticals (NASDAQ:LBPH) with a Outperform and raises the price target from $57 to $80.
U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for bexicaserin for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs)
Evercore ISI Group analyst Josh Schimmer maintains Longboard Pharmaceuticals (NASDAQ:LBPH) with a Outperform and raises the price target from $44 to $57.
Cantor Fitzgerald analyst Josh Schimmer reiterates Longboard Pharmaceuticals (NASDAQ:LBPH) with a Overweight and maintains $60 price target.
B. Riley Securities analyst Kalpit Patel maintains Longboard Pharmaceuticals (NASDAQ:LBPH) with a Buy and raises the price target from $30 to $36.
HC Wainwright & Co. analyst Patrick Trucchio reiterates Longboard Pharmaceuticals (NASDAQ:LBPH) with a Buy and maintains $60 price target.
Bexicaserin achieved an overall median seizure reduction of 56.1% in countable motor seizures over an approximate 6-month treatment period; participants randomized to the PACIFIC placebo group achieved a median seizure reduction of 57.3%Favorable safety and tolerability results observed100% of participants who completed the PACIFIC Study entered the OLEEnd of Phase 2 Meeting scheduled for this summer
SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the appointment of Dr. Randall Kaye as Chief Medical Officer (CMO). Dr. Philip Perera, who has led the clinical development and medical affairs activities since the launch of Longboard, has retired as CMO while remaining with Longboard in an advisory role. "On behalf of the board, shareholders, and our employees, I want to thank Phil for his tremendous contributions," said Kevin R. Lind, Longboard's President and Chief Executive Officer. "His outstanding leade
Initiated the Phase 1b/2a PACIFIC Study, evaluating LP352 in participants with developmental and epileptic encephalopathies (DEEs)LP352 demonstrated statistically significant reduction of epileptiform event frequency and duration in the scn1lab zebrafish model of Dravet syndromeLP659 IND submission remains on track for second half of 2022Cash position expected to support operations into 2024 based on current business plan SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported financ
SAN DIEGO, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the appointment of Jane Tiller, MBChB, FRCPsych, to its board of directors. "We are thrilled to further strengthen the deep expertise of our Board with the addition of Dr. Tiller. Jane brings knowledge across multiple therapeutic areas including neuroscience, and a deep understanding and successful track record in strategy and execution in global clinical development and medical affairs," stated Kevin R. Lind, Longboard's President and Chief Executive Officer.
The proposed acquisition represents a significant step forward in Lundbeck's Focused Innovator strategy, adding a highly innovative and complementary product in late-stage development for Developmental and Epileptic Encephalopathies (DEEs) - an area of high unmet medical need The acquisition will enhance and complement Lundbeck's capabilities and presence within neuro-rare conditions The lead asset, bexicaserin, holds blockbuster potential and is in development for the treatment of DEEs in a program enrolling patients diagnosed with Dravet syndrome, Lennox-Gastaut syndrome, and other DEE syndromes Bexicaserin has shown encouraging anti-seizure effects to date in preclinical and clini
Bexicaserin (LP352) received Breakthrough Therapy designation (BTD) for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) for patients two years of age or older Bexicaserin demonstrated a sustained, durable response in seizure reduction and a favorable safety and tolerability profile across a broad range of DEEs in an interim analysis of the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Completed End of Phase 2 Meeting to discuss Longboard's global Phase 3 program for bexicaserin, which is on track to initiate in H2 2024 Longboard plans to host an Investor & Analyst Event on September 16 to highlight details of the global P
Conference call to discuss corporate updates, including Phase 1 single ascending dose (SAD) topline data for LP659 in healthy volunteers Conference call and webcast to be held August 1 at 4:30pm ET (1:30pm PT) Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it plans to release second quarter 2024 financial results and provide a corporate update, including topline Phase 1 SAD data for LP659, its centrally acting, highly selective sphingosine-1-phosphate (S1P) receptor modulator, on August 1, 2024. The Company will host a conference call and we
Bexicaserin achieved a median seizure reduction of 53.3% in countable motor seizures compared to 20.8% in the placebo group across the DEE study population A median seizure reduction of 72.1% in Dravet Syndrome (DS), 48.1% in Lennox-Gastaut Syndrome (LGS) and 61.2% in DEE Other was achieved Favorable safety and tolerability results Longboard is rapidly moving forward with preparations for its global Phase 3 program Conference call and webcast to be held today at 8:30am ET Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced positive topline da
• Conference call and webcast to be held tomorrow, January 2, at 8:30am ET (5:30am PT) Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will host a conference call to discuss topline data from the PACIFIC Study, a Phase 1b/2a clinical trial evaluating bexicaserin (LP352) in participants with a broad range of Developmental and Epileptic Encephalopathies (DEEs). Bexicaserin is a potentially best-in-class, oral, novel, 5-HT2C receptor superagonist with no observed impact on 5-HT2B and 5-HT2A receptor subtypes. Conference Call and Webcast Details
Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it plans to release 2022 financial results and provide a corporate update on March 2, 2023. The Company will host a conference call at 4:30pm ET (1:30pm PT) on the same day. CONFERENCE CALL DETAILS: Live Call Participation: To join the live call by phone, please pre-register via this link, complete the brief online registration form, and select your preferred method for joining the call. Upon registering you will receive the dial-in info and a unique PIN to join the call, as well as an email confirma
Pipeline Advancement Continues with Ongoing Phase 2 Studies for Voriconazole and Tacrolimus Programs Partnership Activity Surrounding Thin Film Freezing Continues to Expand Reflecting the Technology's Broad Applicability Across Molecule Type and Therapeutic Area Appoints Life Sciences Executive, Brandi Roberts, to Board of Directors and Anthony Hickey, Ph.D. as Chief Scientific Officer Expands Leadership Team With Senior Appointments in Product Development and Manufacturing, Government and Strategic Initiatives, and Regulatory Affairs Conference Call and Webcast Scheduled Today, Thursday, March 24, 2022, at 4:30 PM ET FORT WORTH, Texas, March 24, 2022 (GLOBE NEWSWIRE) -- TFF Pharma